Audiogenic Seizure Mouse Model
Objective: To assess seizure protection by LEV derivatives in an audiogenic mouse model of epilepsy and correlate binding affinity to SV2A with anticonvulsant efficacy
This is a Audiogenic Seizure Mouse Model protocol using mouse as the model organism. The procedure involves 5 procedural steps, 1 equipment items, 4 materials. Extracted from a 2004 paper published in Proceedings of the National Academy of Sciences.
Model and subjects
mouse • Not specified in provided text • unknown • Not specified in provided text • Not specified in provided text
Study window
Estimated timing pending
Core workflow
Prepare brain membranes and synaptic vesicles • Perform photoaffinity labeling • Test LEV binding to SV2A in fibroblasts
Primary readouts
- Binding of tritiated LEV derivative to brain membranes and synaptic vesicles
- Apparent molecular mass of LEV-binding site (≈90 kDa)
- Binding specificity to SV2A versus SV2B and SV2C isoforms
- Binding affinities of LEV derivatives to SV2A in fibroblasts
Key equipment and reagents
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Prepare brain membranes and synaptic vesicles
Isolate brain membranes and purified synaptic vesicles from wild-type and SV2A knockout mice for binding studies
Note: Samples prepared from both wild-type and knockout mice to determine necessity of SV2A for LEV binding
View evidence from paper
“Brain membranes and purified synaptic vesicles from mice lacking SV2A do not bind a tritiated LEV derivative”
Perform photoaffinity labeling
Conduct photoaffinity labeling of purified synaptic vesicles to determine apparent molecular mass of LEV-binding site
Note: Binding site identified as approximately 90 kDa molecular mass
View evidence from paper
“photoaffinity labeling of purified synaptic vesicles confirms that it has an apparent molecular mass of ≈90 kDa”
Test LEV binding to SV2A in fibroblasts
Express SV2A in fibroblasts and test binding of LEV and related compounds to determine sufficiency of SV2A for LEV binding
Note: No binding observed to related isoforms SV2B and SV2C, confirming specificity to SV2A
View evidence from paper
“LEV and related compounds bind to SV2A expressed in fibroblasts, indicating that SV2A is sufficient for LEV binding. No binding was observed to the related isoforms SV2B and SV2C”
Measure binding affinities of LEV derivatives
Determine binding affinities of a series of LEV derivatives to SV2A in fibroblasts and to the LEV-binding site in brain tissue
Note: High degree of correlation observed between fibroblast and brain binding affinities
View evidence from paper
“there is a high degree of correlation between binding affinities of a series of LEV derivatives to SV2A in fibroblasts and to the LEV-binding site in brain”
Assess seizure protection in audiogenic mouse model
Test LEV derivatives in audiogenic seizure model to evaluate anticonvulsant efficacy and correlate with SV2A binding affinity
Note: Strong correlation found between SV2A affinity and seizure protection ability
View evidence from paper
“there is a strong correlation between the affinity of a compound for SV2A and its ability to protect against seizures in an audiogenic mouse animal model of epilepsy”